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Abstract: Epithelial Ovarian Cancer (EOC) is one of the leading causes of cancer-related deaths 
among women and is characterized by the diffusion of nodules or plaques from the ovary to the 
peritoneal surfaces. Conventional therapeutic options cannot eradicate the disease and show low 
efficacy against resistant tumor subclones. The treatment of liquids via cold atmospheric pressure 
plasma enables the production of plasma-activated liquids (PALs) containing reactive oxygen and 
nitrogen species (RONS) with selective anticancer activity. Thus, the delivery of RONS to cancer 
tissues by intraperitoneal washing with PALs might be an innovative strategy for the treatment of 
EOC. In this work, plasma-activated Ringer’s Lactate solution (PA-RL) was produced by exposing 
a liquid substrate to a multiwire plasma source. Subsequently, PA-RL dilutions are used for the 
treatment of EOC, non-cancer and fibroblast cell lines, revealing a selectivity of PA-RL, which 
induces a significantly higher cytotoxic effect in EOC with respect to non-cancer cells. 
Keywords: cold atmospheric pressure plasma; plasma medicine; plasma-activated Ringer’s lactate 
solution; ovarian cancer; cytotoxicity; selectivity 
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1. Introduction 
Epithelial Ovarian Cancer (EOC) is a relatively rare disease with the highest incidence rate in 
Western countries such as Europe and North America (8 cases per 100,000) [1]. It is the most lethal 
and silent gynecological tumor that originates from the epithelium of the ovary, fallopian tubes or 
the peritoneum [2,3]. About 75% of affected women are diagnosed at advanced stages (III-IV) [3], 
with a survival rate of 29% within 5 years from diagnosis [4,5]. Furthermore, the spread of cancer to 
secondary sites is a common complication that contributes to the diffusion of the disease to the 
peritoneal cavity [6,7]. Standard of care in advanced EOC, since the 1980s, is the combination of 
surgical cytoreduction followed by first-line platinum-taxane chemotherapy [5,8]. Despite the 
improvements in survival rates [9], these conventional therapies cannot eradicate the disease [4,8]. 
However, innovations in the surgical and pharmacological field are creating the conditions to treat 
this type of neoplastic invasion. This could be accomplished by infusing chemotherapy directly in 
the peritoneal cavity during surgery, such as in the case of Hyperthermic Intraperitoneal 
Chemotherapy (HIPEC) [4,9–12]. This procedure allows one to perform a washing of the abdominal 
cavity by delivering locally a chemotherapeutic solution [13,14]. Despite the promising results of 
intraperitoneal chemotherapy administration, the development of efficacious solutions is a cogent 
issue in order to limit severe drug side effects and overcome chemoresistance. 
Plasma-activated liquids (PALs) are produced by electrical discharge in the gas–liquid interface; 
when high voltage is applied, plasma filaments are generated in the gas phase, leading to the 
formation of a flow of free radicals, electrons, ions, reactive species and UV radiation. The exposure 
of a liquid to a plasma induces the production of reactive oxygen and nitrogen species (RONS), like 
nitrites (NO2ˉ), nitrates (NO3ˉ), peroxynitrites (OONOˉ) ozone (O3), singlet oxygen (·O2), hydroxyl 
radicals (·OH) and hydrogen peroxide (H2O2) [15]. These RONS have been shown to exert a 
significant role in cancer therapy due to their triggering of cell death mechanisms [16,17]. It was 
observed in vitro and in vivo that PALs can induce a selective anticancer effect [18–20] likely related 
to the different basal ROS concentration in cancer and non-cancer cells, as the higher metabolic status 
typical of cancer cells would render them unable to tolerate any increase in oxidative stress, such as 
the one caused by RONS in PALs [21,22]. 
PAL treatments turned out to be effective in terms of anti-tumor activity against EOC cells, 
inhibiting their proliferation and compromising their metastatic potential [20,21,23,24]. In the 
perspective to propose PALs in clinical applications, it is necessary to select liquids to be exposed to 
plasma suitable to the clinical phase, such as physiological or Ringer’s Lactate solutions (RL), an 
intravenous fluid usually used to treat hypovolemia and metabolic acidosis [25]. Tanaka et al. [26] 
first proposed the use of RL, whose simple composition (NaCl, KCl, CaCl2 and lactate) makes it 
adoptable for the production of PAL, avoiding the possible influence of more organic medium 
components on its final biological effect [27]. It has been demonstrated that plasma-activated Ringer’s 
Lactate solutions (PA-RL) exhibit an anti-tumor effect in lung, mammary, ovarian cancer cells as well 
as in glioblastoma in vitro [25,26,28], and in pancreatic and cervical cancer in vivo [26,29]. Several 
studies demonstrated that the effects of PA-RL may be ascribed to RONS, together with the activation 
of lactate [26,28]. All these results suggest that the use of PA-RL may represent a new potential 
therapeutic strategy for intraperitoneally disseminated cancers. Nonetheless, PA-RL selective 
cytotoxicity on EOC cells remains to be assessed. Indeed, the capability of an anti-neoplastic drug to 
act exclusively on cancer cells is essential to preserve the healthy tissue counterpart, [23,30,31], 
making this aspect one of the most important for the application of PA-RL to EOC treatment [25]. 
In this study, RL was exposed to plasma generated by a multiwire plasma source used for the 
first time to produce PA-RL. EOC and non-cancer cells lines were subjected to treatment with PA-RL 
dilutions in order to evaluate their sensitivity and define a PA-RL selective window. Moreover, we 
dissected whether PA-RL-induced cell injury may depend on two of the major produced and studied 
reactive species (H2O2 and NO2ˉ), or on the pH change caused by RL. Hence, we further showed that 
the response of our models to the high oxidative stress caused by PA-RL treatment may be explained 
analyzing the antioxidant response, which may point to the mechanisms responsible for cancer cells-
specific PA-RL toxicity. 
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2. Results 
2.1. Electrical Characterization of the Multiwire Plasma Source and Chemical Features of PA-RL 
To evaluate the average power of the plasma discharge, the temporal evolution of voltage and 
current waveforms was recorded during the treatment of RL solution (Figure 1a). Subsequently, data 
were used for the calculation of the average power as a function of the applied voltage (Figure 1b); 
the resulting function presents a quadratic behavior according to B. Dong et al. [32]. 
 
Figure 1. Electrical characterization of plasma source during treatment of Ringer’s Lactate (RL) 
solution: (a) representative voltage (red) and current (blue) waveforms at 18 kV and 1 kHz and (b) 
power values as a function of the applied voltage. Data are presented as mean ± SEM (n = 3). 
RONS variation induced by plasma treatment for different average power values is shown in 
Figure 2a: the concentration of both H2O2 and NO2ˉ measured in the liquid phase resulted in not being 
affected by the average power in the range of 7.85-12.54 W. Conversely, they strongly depended on 
the treatment time (Figure 2b). More specifically, the H2O2 and NO2ˉ concentrations increased linearly 
with the treatment time and reached a maximum of 226 ± 12.46 μM and 659 ± 15.19 μM, respectively. 
Furthermore, the ratio NO2ˉ/H2O2 was 2.91 in the liquid treated for 10 min.  
 
Figure 2. Plasma treatment leads to the formation of H2O2 and NO2ˉ. (a) Reactive oxygen and nitrogen 
species (RONS) concentration as a function of the average power after 10 min of plasma treatment. 
Data are presented as mean ± SEM (n = 3). (b) H2O2 and NO2ˉ concentrations as a function of treatment 
time. Data are presented as mean ± SEM (n = 3) and statistical significance is specified with asterisks 
(** p ≤ 0.001 as determined by a paired Student’s t-test, versus the 5 min treatment). 
In addition, pH and conductivity of the PA-RL and its dilutions are reported in Figure 3. After 
10 minutes of plasma treatment, PA-RL pH decreased to 5.36 (PA-RL) (Figure 3a), whereby only 
dilutions starting from 1:4 were used for subsequent cell treatments. Plasma also induced an increase 
of conductivity up to 15.13 mS/cm (Figure 3b). 
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Figure 3. Chemical characterization of plasma-activated RL (PA-RL) and its dilutions after 10 min of 
plasma treatment at 18 kV. (a) pH and (b) conductivity as a function of serial dilutions. Data are 
presented as mean ± SEM (n = 3). 
2.2. Evaluation of Plasma Discharge Behavior and Emission by means of Low-Speed and High-Speed Filter 
Imaging  
Low-speed imaging was performed to assess the global behavior of plasma filaments generated 
during the treatment. Plasma discharge consisted of random streamers generated between the wire-
electrodes and impinging on the liquid surface (Figure 4a). To further investigate the plasma 
discharge, a high-speed camera equipped with a 402 nm filter was used to visualize the emission of 
plasma in contact with the RL during treatment. The filter wavelength was selected to highlight 
specifically the emission of vibrationally excited nitrogen molecules, precursors of reactive nitrogen 
species generated in the liquid phase. In Figure 4b representative HS filter images of the multiwire 
discharge generated applying different voltages are shown. In all investigated cases, it is possible to 
observe that single filaments were randomly generated between the high voltage wire electrode and 
the liquid surface. Moreover, no relevant differences could be observed upon varying the input 
voltage between 15 and 18 kV. 
 
Figure 4. Low-speed images and high-speed (HS) filter images of the multiwire plasma discharge 
during RL treatment. (a) Picture of plasma generated during the treatment of PA-RL with an applied 
voltage of 18 kV and 30 fps. (b) HS filter images of plasma filaments for different values of applied 
voltage (between 15 to 18 kV) and 100 fps. 
2.3. PA-RL Displays a Cytotoxic Effect on EOC Cell Lines, Which Does not Depend exclusively on 
Hydrogen Peroxide or Nitrites 
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We first tested three different PA-RL dilutions (1:4, 1:8 and 1:16) on two different EOC cell lines, 
namely OV-90 and SKOV-3, over time, with the aim to understand if PA-RL exerted a cytotoxic effect 
and if this was dependent on the dilution, i.e., on the concentration of reactive species to which cells 
were exposed. After two hours of exposure to PA-RL, both OV-90 and SKOV-3 showed a decrease in 
viability only when the 1:4 dilution was used, whereas only OV-90 appeared to respond early to PA-
RL even at higher dilutions. Both OV-90 and SKOV-3 cells were observed to be similarly affected in 
terms of viability when treated with the three PA-RL dilutions after 72 hours of exposure, displaying 
a dose-dependent response that was more evident in the OV-90 cell line, and showing a dramatic 
decrease in viability, which was between 80% and 95% in the two cell lines, even with the more 
diluted PA-RL (1:16, Figure 5a). Overall, SKOV-3 cells only initially appeared to be less sensitive to 
the treatment, as their viability decreased in time in a more delayed fashion, unlike OV-90, but at 72 
hours both cell populations showed to be severely affected by PA-RL. The viability of both EOC cell 
lines at 24 and 48 hours after treatment is shown in Supplementary Figure 1a to highlight the time-
dependent effect. 
We hence decided to verify whether the cytotoxic effects of PA-RL could be ascribed mainly to 
either of the two components we could easily compare PA-RL with, namely hydrogen peroxide and 
nitrites. The scope of this analysis was to understand whether the complexity of PA-RL might be 
substituted by a simpler solution of one of the two components, such as for instance H2O2, more 
readily available in hospital settings. We also verified whether the observed toxicity may be due to 
pH change: we hence obtained RL solutions containing hydrogen peroxide and nitrites at the same 
concentrations as measured in the PA-RL 1:16 dilution, as the latter was shown to have a toxic effect 
on cancer cells. A RL solution of the same pH of the 1:16 dilution was prepared to which both OV-90 
and SKOV-3 were exposed for 2 h, then cultured for the subsequent 72 hours. In these conditions, 
OV-90 cells were confirmed to undergo a more immediate decrease in viability, consistent among the 
different treatments, of about 20%–30% after 2 hours exposure, whereas SKOV-3 cells appeared to 
suffer only from a mild to no loss of viability during the same time frame (Figure 5b). After 72 hours, 
nitrites were not shown to have any effect on cell viability for both cancer cell lines, whereas pH and 
H2O2 only mildly inhibited growth with respect to both nitrites and control. We overall validated that 
only PA-RL was able to dramatically reduce viability of both cancer cell lines (Figure 5b), suggesting 
the different RONS therein contained may have a synergistic effect in the induction of cytotoxicity, 
and that the complexity of the PA-RL may not be substituted by the synthetic solutions we here 
utilized. 
2.4. PA-RL Is Selective for EOC Cells 
In order for PA-RL to find application in the clinics, one of the main requisites to be fulfilled is 
that its cytotoxic action ought to be specific for cancer cells, while sparing non-cancer cells, 
particularly those of the connective tissues, so to allow recovery of the wounds within the pelvic 
cavity. We hence next questioned whether our PA-RL may display such a specific effect, and 
attempted to prove so by using two different cell models, namely the non-cancer epithelial cell lines 
of ovarian origin (HOSE), as the counterpart for both EOC models, and two different human 
immortalized fibroblast lines, to gauge the response to PA-RL of the tissue mesenchymal component. 
Therefore, we tested the same three different PA-RL dilutions at the same time points as the EOC cell 
lines; surprisingly, we observed a similar rate of decrease of both fibroblasts and HOSE cells with 
respect to their viability, which was evident as a late response (i.e., not observed at the 2 hours 
exposure), in a dose-independent fashion at 72 hours, ranging between 60% and 70%, with the highest 
survival at the 1:16 dilution (Figure 5c, Figure S1b). The 1:16 dilution, therefore, was deemed as the 
best compromise to obtain a high degree of mortality in cancer cells while sparing both the non-
cancer epithelial population and fibroblasts. Indeed, when we compared the decrease in cell viability 
of cancer versus non-cancer cells, the effects of PA-RL were shown to be significantly different (Figure 
5d, Figure S1c).  
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2.5. Differentially Activated Antioxidant Defenses Mechanisms May Underlie Cancer Cells-Specific PA-RL 
Toxicity 
Last, we attempted to understand the mechanisms underlying the different responses in terms 
of the viability of cancer with respect to non-cancer cells. It is widely accepted that cancer cells 
withstand a higher degree of oxidative stress during their fast proliferation, for which they have been 
shown in several contexts to display higher levels of antioxidant proteins. The latter should act as a 
defense mechanism against the excess of radical species, since overloading neoplastic cells with 
radicals may lead to an oxidation-mediated collapse [33]. 
We hence measured the levels of one of the most active cytosolic antioxidant enzymes involved 
in radical species detoxification, namely superoxide dismutase-1 (SOD-1), both in the two EOC cell 
lines and in human fibroblasts, to ascertain if indeed cancer cells expressed higher levels of the 
protein (Figure 6a, Figure S2). As expected, we observed increased levels of SOD-1 in cancer cells 
versus human fibroblasts, although this did not reach statistical significance in our Western blot 
analysis (Figure 6b, Figure S1d). We then proceeded to treat all four cell lines with PA-RL, or with RL 
alone, and observed the changes in SOD-1 levels at the 72 hours time point. Indeed, a statistically 
significant increase in SOD-1 expression was evident in fibroblasts only, when these cells were treated 
with PA-RL, whereas the levels of the enzyme remained unchanged in cancer cells (Figure 6c, Figure 
S1e), suggesting that here the antioxidant response has likely reached a plateau over which enzymes 
levels may not be increased. Fibroblasts, instead, may be able to adapt to the oxidative burst by 
increasing SOD-1 levels, albeit proving this unequivocally warrants further functional experiments. 
It must be noted that, although not statistically significant, a trend for an increase in SOD-1 levels in 
fibroblasts but not in cancer cells may be observed in response to RL treatment alone, with a similar 
fold increase as with PA-RL (Figure 6c, Figure S1e). 
On one hand, this may indicate that RL treatment may be synergistic with PALs to trigger an 
antioxidant response; on the other, it is of modest relevance what is the causative hit to induce such 
an enzymatic increase, since the activated mechanism would still be protective against RONS. 
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Figure 5. PA-RL displays a selective cytotoxic effect on Epithelial Ovarian Cancer (EOC) cell lines. (a) 
Viability of SKOV-3 (n = 7) and OV-90 (n = 9) cell lines treated with PA-RL dilutions (1:4, 1:8 and 1:16). 
Data are mean ± SEM normalized on the corresponding control in RL (CTR-RL). (b) Viability of 
SKOV-3 and OV-90 cell lines treated with PA-RL 1:16 and synthetic solutions at dilution 1:16. H2O2-
supplemented RL, NO2ˉ-supplemented RL and pH-adjusted RL solutions were diluted in RL to obtain 
the final treatment solutions. Data are mean ± SEM (n = 3) normalized on the corresponding CTR-RL. 
(c) Viability of non-cancer cells, namely human fibroblasts (n = 9) and HOSE (n = 4) treated with 
different PA-RL dilutions (1:4, 1:8 and 1:16). Data are mean ± SEM normalized on the corresponding 
CTR-RL. (d) PA-RL 1:16 efficacy on cell viability in non-cancer and EOC cell lines. Cell viability was 
normalized to the CTR-RL at 2 hours and plotted as percentage relative to the corresponding CTR-
RL, for both time points. In each panel, data are mean ± SEM and statistical significance is specified 
with asterisks (* p ≤ 0.05, ** p ≤ 0.001 as determined by a paired Student’s t-test). 
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Figure 6. PA-RL solution induces an increase in Superoxide Dismutase-1 (SOD-1) expression in 
fibroblasts but not in EOC cell lines. (a) Western blot analysis of EOC cell lines and fibroblasts (F1 and 
F2) at 72 hours after treatment with PA-RL 1:16 (UT, untreated cells). A representative experiment of 
three is shown. (b) SOD-1 levels in untreated fibroblasts and cancer cell lines. Histograms show 
densitometric values of the SOD-1 protein normalized to the β-actin used as a loading control. All 
data are presented as mean ± SEM of three independent experiments. (c) Relative densities of SOD-1 
and β-actin were measured using densitometric analysis. SOD-1 levels of CTR-RT and PA-RL 1:16 
after 72 h of treatment were normalized to β-actin and plotted as fold change relative to the untreated 
(UT) sample. All data are presented as mean ± SEM of three independent experiments. Statistical 
significance is specified with asterisks (* p ≤ 0.05 as determined by a paired Student’s t-test). 
3. Discussion 
In this work, we produced a PA-RL through a multiwire plasma source, whose main innovative 
feature is its ability to work without the use of a technical gas, while allowing to treat 20 mL of liquid 
[28,34–36]. Moreover, the source architecture we here propose can be easily scaled in order to produce 
volumes of activated solution higher than 20 mL. The interaction of plasma discharges with liquid 
substrates leads to the formation of a high concentration of RONS [37,38]; these latter are formed in 
chemical reactions involving species generated in the plasma (gas phase) and diffusing into the 
liquid. As an example, the formation of NO2ˉ involves the gas phase reaction of NO with OH 
molecules, resulting in the production of HNO2 that dissolves in the liquid phase and leads to the 
formation of NO2ˉ. While atmospheric NO is generally produced via the Zeldovich mechanism and 
requires high temperatures (1300 °C), the same process in non-equilibrium plasma can take place 
close to room temperature due to the production of a high number of vibrationally excited N2 
molecules [38]; the presence of these molecules favors the breakage of N-N bonds to release N atoms 
that react with O2 and ·O to produce NO. As shown by M. Simek et al. in the case of a plasma discharge 
working in environmental air, vibrationally excited N2 molecules emit light at a wavelength around 
400 nm (second positive system, C3Πu→B3Πg) [39]. In this respect, Figure 4b confirms the presence of 
vibrationally excited N2 molecules and thus the gas phase origin of the NO2ˉ measured in the PAL. 
The plasma treatment of RL induced the production of RONS and a decrease of pH, and PA-RL was 
tested on both cancer and non-cancer cells in vitro to validate a cytotoxic effect specific for EOC cells. 
The issue of selectivity in the search for anticancer therapies has always been a cogent one, and 
a plethora of research lines have focused on detecting the molecular differences between normal and 
transformed cells on which to design a targeted approach. One such difference has been shown to be 
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the capacity of cancer cells to withstand the oxidative stress they come to face due to their metabolic 
rewiring, their high proliferation rate, and to the microenvironment conditions that quickly build up 
around a progressing tumor mass [33,40]. Albeit our data are preliminary in terms of understanding 
the molecular causes for a relevant degree of selectivity of PA-RL, they point to a different ability of 
non-cancer cells to regulate the enzymatic milieu responsible for reactive species detoxification, 
unlike in neoplastic cells. This may reveal the triggering of a salvage mechanism when a boost of 
RONS is provided from external sources. Of note, we did wonder whether hydrogen peroxide alone, 
or nitrites, may have the same effect as PA-RL, but we showed this not to be the case, pointing to the 
need for a complex source of RONS to achieve the steep decrease in viability we observed in our cell 
models. 
Whatever the cause, which warrants further investigation, we believe our most relevant data are 
those showing a consistently higher effect of the PA-RL we generated and characterized on the two 
OC cells lines compared to both non-cancer ovarian cells and fibroblasts. In this regard, the ability of 
PAL to suppress ovarian cancer metastases when injected intraperitoneally in a mouse model was 
previously reported [24]. Yet, no evidence is available on the safety of PAL intraperitoneal 
administration in humans [41], supporting the need to shift the main focus of the plasma onco-
medicine on liquids applicable to the clinical practice. This holds particularly true in OC, where 
spreading of the advanced stage disease within the pelvic cavity of the patient is often the case 
through the occurrence of micro-lesions [42], as washing the cavity with PA-RL may significantly 
reduce tumor burden, while sparing the non-cancer component. 
4. Materials and Methods 
4.1. Plasma Device and Electrical Characterization 
PA-RL was produced by exposing RL (Fresenius Kabi Italia S.r.l.) to a micropulsed plasma 
discharge (Figure 7a). The high voltage electrodes consist of four steel wires individually fixed on 
aluminum supports and connected to high voltage generator through a ballast resistor of 70 kΩ; while 
the ground electrode consists of an aluminum sheet fixed on the bottom of the 5 mm thickness vessel 
containing the liquid substrate and is connected to the ground through a resistor of 30 kΩ. A 
polymethylmethacrylate (PMMA) box encased the plasma source to guarantee a controlled 
atmosphere during treatment; moreover, the box was equipped with a fan. 
The setup reported in Figure 7b was used to measure the time evolution of the plasma discharge 
electrical parameters using a 5 mm gap value between the high voltage electrodes and the liquid 
surface. The plasma device was driven by a micropulsed high voltage generator (AlmaPULSE, 
AlmaPlasma s.r.l., Bologna, Italy) delivering a peak voltage of 18 kV, pulse duration FWHM (Full 
Width at Half Maximum) of 8 μs and pulse repetition rate set at 1 kHz. In addition, a high voltage 
probe (Tektronix P6015A) was used to measure the voltage, while the discharge current was 
measured by the means of a current probe (Pearson 6585). Both probes were connected to an 
oscilloscope (Tektronix DPO 40034). The average power (P) over a period (T) was calculated starting 
from current (I) and voltage (V) measurements: 
𝑃 = 1𝑇න𝑉𝐼 𝑑𝑡 ்  (1)
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Figure 7. (a) Illustration of the high voltage electrodes and RL and (b) layout of the setup used for 
electrical characterization. 
4.2. PA-RL and Synthetic Solutions Production 
20 mL of RL were exposed to plasma for 10 minutes using a 5 mm gap between the high voltage 
wire electrodes and the liquid surface to produce PA-RL. The pulse repetition frequency (PRF) was 
fixed at 1 kHz, while the peak voltage (PV) was set at 18 kV with fan always on. After plasma 
treatment, quantitative measurements of H2O2 and NO2ˉ were performed using Amplex® Red 
Hydrogen Peroxide Assay Kit (Thermo Fisher Scientific #A22188, Waltham, MA, USA) and 
Nitrite/Nitrate colorimetric assay (ROCHE #11746081001, Basel, Switzerland) [43], respectively. In 
addition, before and after RL exposure to plasma, pH and conductivity were evaluated by the means 
of inoLab® pH 7110 and Oakton Instrument: Con 6+ Meter, respectively. Subsequently, PA-RL was 
diluted by preparing two-fold serial dilutions (1:4, 1:8 and 1:16) in RL and their effect was tested on 
our cell models. 
Synthetic solutions were also prepared; two different RL solutions were supplemented with 226 
μM of H2O2 (Sigma-Aldrich, #216763, St. Louis, MO, USA) and 659 μM of NO2ˉ (Alfa Aesar  by 
Thermo Fisher (Kandel) GmbH, #43015-, Karlsruhe, Germany), the same concentrations generated 
by plasma treatment in PA-RL. An additional synthetic solution was prepared by adjusting the pH 
of RL to 5.36 with a solution of 0.01 M HCl, according to the pH-value gauged in PA-RL. The above 
mixtures were diluted in RL as mentioned before, thereafter EOC cell lines were treated with the 
synthetic solutions at dilution 1:16. 
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4.3. Low-Speed and High-Speed Filter Imaging 
A low-speed camera (Nikon D800, Shinjuku, Tokyo, Japan) was operated at 30 fps for the 
evaluation of the behavior of the plasma discharge, as reported in Figure 4a. The high-speed filter 
imaging setup, employed for the characterization of plasma source (Figure 8), was composed of a 
high-speed (HS) camera (Memrecam GX-3 NAC image technology) operated at 100 fps and 1/200 
shutter time. Additionally, a camera lens (SIGMA 180 MM 1:3.5 APO macro DC HSM) was used and 
a 402 nm filter (CHROMA ET402/15x, #327585, Bellows Falls, VT, USA) was positioned in front of the 
latter to evaluate the emission of N2(C3Πu→B3Πg) second positive system near 400 nm. During HS-
filter imaging, the focus of the acquisitions was set in correspondence of the electrode closer to the 
filter. 
 
Figure 8. High-speed filter imaging setup. 
4.4. Cell Lines and Culture Conditions 
Human EOC cell lines SKOV-3 and OV-90 were purchased from ATCC® (Manassas, VA, USA). 
The HOSE cell line was purchased from ScienCell Research Laboratories, Inc (Carlsbad, CA, USA). 
and two lines of immortalized fibroblasts (F1 and F2) derived from two patients skin biopsies, 
obtained within the context of a study approved by the Independent Ethics Committee of the S. 
Orsola Hospital (107/2011/U/Tess) were used as non-cancer controls. 
EOC cell lines, HOSE and fibroblasts were grown respectively in Roswell Park Memorial 
Institute 1640 medium (RPMI, EuroClone, Milan, Italy), Ovarian Epithelial Cell Medium (OEpiCM, 
ScienCell Research Laboratories, Inc., Carlsbad, CA, USA) and Dulbecco’s modified Eagle’s medium 
(DMEM High glucose, EuroClone). They were all supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin 
(EuroClone). Cells were maintained in an incubator with a humidified atmosphere of 5% CO2 at 37 
°C. 
4.5. Cell Treatment and Viability Assay 
SKOV-3 (2 × 103 cells/well), OV-90 (4 × 103 cells/well), HOSE (7 × 103 cells/well), F1 (9 × 103 
cells/well) and F2 (1 × 104 cells/well) were seeded in 96-well plates in complete medium. After 24 
hours, cells were treated with 100 μL of freshly produced PA-RL at different dilutions (1:4, 1:8 and 
1:16) and RL. After 2 hours of treatment, cells were washed with phosphate buffered solution (PBS) 
and cultured in complete medium at 37 °C and 5% CO2. Cell viability was assessed after the exposure 
of cells to treatments and measured by using Sulforhodamine B (SRB; Sigma-Aldrich, #S1402, St. 
Louis, MO, USA) assay at 2, 24, 48 and 72 hours after treatment. Treated cells were fixed with 50% 
cold trichloroacetic acid (TCA) for 1 hour, washed 5 times with distilled water to eliminate TCA, and 
stained with 0.4% SRB for 30 minutes. Protein-bound dye was dissolved in 10 mM pH 10.5 Tris base 
solution after four washes with 1% acetic acid to remove unbound dye. SRB was used to determine 
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cell density, based on the measurement of cell protein content. Absorbance values were determined 
at 570 nm using a 96-well Multilabel Plate Reader VICTOR3 (1420 Multilabel Counter-PerkinElmer, 
Turku, Finland). The percentage of viability was calculated considering RL-treated cells as the control 
(CTR-RL). 
4.6. SDS-PAGE and Western Blot Analysis 
Cells were seeded and after 24 hours treated with RL solution and freshly produced PA-RL 1:16 
dilution. At this point, an untreated (UT) sample was collected for each cell lines. Two hours after 
treatments, cells were washed in PBS and cultured in their own complete medium at 37 °C and 5% 
CO2. After 72 hours, CTR-RL and PA-RL treated samples of each cell line were collected. Total lysate 
was obtained by using RIPA buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1% SDS, 1% Triton X-
100 and 1 mM EDTA pH 7.6) supplemented with protease inhibitors (ThermoFisher #A32955, 
Waltham, MA, USA). The protein concentration was determined by a Lowry protein assay (Bio-Rad 
#5000116, Hercules, CA, USA). Proteins (30 μg) were separated by using SDS-PAGE on a 12% 
polyacrylamide gel and then transferred onto a Trans-Blot Turbo Midi Nitrocellulose membrane (Bio-
Rad #1704159). Membranes were blocked with 5% TBS-Tween/milk (0.1% Tween 20 (Sigma-Aldrich 
#P9416, , St. Louis, MO, USA) in Tris Buffered Saline and incubated with the anti-SOD-1 1:1000 (Santa 
Cruz Biotechnology #sc-11407, Dallas, TX, USA) overnight at 4 °C and subsequently with anti-β-actin 
1:10000 (Sigma-Aldrich #A5316) for 1 hour at room temperature (RT)). Membranes were washed four 
times for 5 minutes using TBS-Tween and then incubated with secondary antibodies (Jackson 
ImmunoResearch Laboratories #111035144 and #111035146, West Grove, PA, USA), diluted 1:20000 
(anti-rabbit) and 1:10000 (anti-mouse) in TBS-Tween for 30 minutes at RT. Development was 
performed by using Clarity Western ECL Substrate (Bio-Rad #1705061) and exposing with ChemiDoc 
XRS+ (Bio-Rad). Protein levels were determined by densitometry of each specific band normalizing 
on β-actin signal by using ImageJ software (Version 1.5Oi, Bethesda, MD, USA). 
4.7. Statistical Analyses 
Statistical analyses were performed using a Student’s t-test. The results were expressed as the 
mean ± standard error of the mean (SEM; n ≥ 3). 
5. Conclusions 
New therapeutic approaches for the treatment of EOC involve the combination of multiple 
therapies (chemotherapy, antiangiogenic agents and PARP inhibitors). Ovarian cancer cells, 
however, thrive as they develop resistance against current drugs, through mechanisms that are 
currently unclear, hence decreasing the long-term efficacy of therapies. Treatment of liquids by 
means of cold atmospheric pressure plasma, due to their content of RONS, may respond to the 
requirement for new types of active treatments against ovarian cancer, which may be used in 
combination with other standard therapies. In this context, the novelty of our approach lies in the use 
of a well-known clinically suitable fluid, namely RL. We reported that PA-RL produced by exposing 
RL to plasma has a degree of selectivity for cancer cells compared to fibroblasts, although further 
investigations need to confirm the exact mechanism underlying such preferential activity. 
In conclusion, albeit far from clinical practice, PA-RL may represent a good candidate to respond 
to the requirement for novel therapies with a local administration, which act on cancer cells with 
reduced damage on the surrounding healthy tissues. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Viability of 
(a) SKOV-3 (n = 7) and OV-90 (n = 9) and (b) fibroblasts (n = 9) and HOSE (n = 4) cells treated with PA-RL dilutions 
(1:4, 1:8 and 1:16). Data are mean ± SEM normalized on its respective control in RL (CTR-RL). (c) PA-RL 1:16 
efficacy on cell viability in SKOV-3, OV-90, fibroblasts and HOSE cells at 2, 24, 48 and 72 hours after treatment. 
Cell viability was normalized to the CTR-RL at 2 hours and plotted as percentage relative to corresponding CTR-
RL, for both time points. Data are mean ± SEM. (d) SOD-1 levels in untreated fibroblasts, SKOV-3 and OV-90 cell 
lines. Histograms represent densitometric values of SOD-1 protein normalized to the β-Actin used as loading 
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control. All data are presented as the mean ± SEM of three independent experiments. (e). Relative densities of 
SOD-1 and β-Actin were measured using densitometric analysis of the western blots. SOD-1 levels of CTR-RT 
and PA-RL 1.16 after 72 h of treatment were normalized to β-Actin and plotted as fold change relative to the 
untreated (UT) sample. All data are presented as the mean ± SEM of three independent experiments (n = 3). 
Statistical significance is specified with asterisks (* p ≤ 0.05, ** p ≤ 0.001 as determined by paired Student t-test), 
Figure S2: Additional information. Uncropped blot showing the different bands with molecular weight markers 
for SOD-1 and β-Actin represented in Figure 6a. The image was acquired using ChemiDoc (Bio-Rad). The 
chemiluminescent blot image was merged with a colorimetric image representing the marker of the same 
Western blot membrane using Image Lab Software (Bio-Rad). 
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